Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

DYAX:US

26.7100 USD 0.0600 0.22%

As of 20:10:00 ET on 05/22/2015.

Company Profile for Dyax Corp (DYAX)

Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. The Company currently has two recombinant proteins, DX-88 and DX-890 in phase II clinical trials.

Contact Information

Dyax Corp

55 Network Drive
Burlington, MA 01803
United States
Phone: 1-617-225-2500
Fax: 1-617-225-2501

Key Executives for Dyax Corp (DYAX)

Gustav A ChristensenPresident/CEOGeorge V MigauskyExec VP/CFO
Burt A AdelmanExec VP/Chief Medical OfcrTodd BazemoreExec VP/Chief Commercial Ofcr
Andrew AsheExec VP/General CounselJennifer RobinsonAssoc Dir:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil